Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience

Abdulhadi Jfri; Cesar A Virgen; Marianne Tawa; Anita Giobbie-Hurder; Thomas S Kupper; David C Fisher; Nicole R LeBoeuf; Cecilia Larocca

doi:10.1016/j.jaad.2023.05.082

Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience

J Am Acad Dermatol. 2023 Nov;89(5):1044-1047. doi: 10.1016/j.jaad.2023.05.082. Epub 2023 Jun 13.

Authors

Abdulhadi Jfri¹, Cesar A Virgen², Marianne Tawa³, Anita Giobbie-Hurder⁴, Thomas S Kupper², David C Fisher⁵, Nicole R LeBoeuf², Cecilia Larocca⁶

Affiliations

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
³ Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
⁴ Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
⁶ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. Electronic address: [email protected].

PMID: 37321484
DOI: 10.1016/j.jaad.2023.05.082

No abstract available

Keywords: CTCL; MAR; Mogamulizumab; Sézary syndrome; cutaneous T cell lymphoma; immune-related adverse events; mycosis fungoides; side effects; skin toxicity.

Grants and funding

R01 AR065807/AR/NIAMS NIH HHS/United States